CK2 inhibitor enhances vitamin D mediated anti-tumor effects

Inhibition of protein kinase CK2 reduces CYP24A1 expression and enhances 1,25-dihydroxyvitamin D₃ anti-tumor activity in human prostate cancer cells

Wei Luo¹, Wei-Dong Yu¹, Yingyu Ma¹, Mikhail Chernov², Donald L. Trump³ and Candace S. Johnson¹,*

Departments of Pharmacology and Therapeutics¹, Small Molecule Screening Core² and Medicine³, Roswell Park Cancer Institute, Buffalo, New York

Running title: CK2 inhibitor enhances vitamin D mediated anti-tumor effects

Key words: 1, 25-dihydroxyvitamin D₃, CYP24A1, protein kinase CK2, prostate cancer

Financial support: This study was supported by NIH/NCI grants CA067267, CA085142 and CA095045.

*Corresponding author:
Candace S. Johnson
Pharmacology and Therapeutics
Roswell Park Cancer Institute
Elm and Carlton Streets, Buffalo, NY 14263
Phone: 716-845-8300
Fax: 716-845-1258
Email: Candace.Johnson@roswellpark.org
Abstract

Vitamin D has broad range of physiological functions and anti-tumor effects. 24-hydroxylase, encoded by the CYP24A1 gene, is the key enzyme for degrading many forms of vitamin D including the most active form, 1,25D₃. Inhibition of CYP24A1 enhances 1,25D₃ anti-tumor activity. In order to isolate regulators of CYP24A1 expression in prostate cancer cells, we established a stable prostate cancer cell line PC3 with CYP24A1 promoter driving luciferase expression to screen a small molecular library for compounds that inhibit CYP24A1 promoter activity. From this screening, we identified, 4,5,6,7-tetrabromobenzimidazole (TBBz), a protein kinase CK2 selective inhibitor as a disruptor of CYP24A1 promoter activity. We show that TBBz inhibits CYP24A1 promoter activity induced by 1,25D₃ in prostate cancer cells. In addition, TBBz downregulates endogenous CYP24A1 mRNA level in TBBz treated PC3 cells. Furthermore, siRNA-mediated CK2 knockdown reduces 1,25D₃ induced CYP24A1 mRNA expression in PC3 cells. These results suggest that CK2 contributes to 1,25D₃ mediated target gene expression. Lastly, inhibition of CK2 by TBBz or CK2 siRNA significantly enhanced 1,25D₃ mediated anti-proliferative effect in vitro and in vivo in a xenograft model. In summary, our findings reveal that protein kinase CK2 is involved in the regulation of CYP24A1 expression by 1,25D₃ and CK2 inhibitor enhances 1,25D₃ mediated anti-tumor effect.
Introduction

The most physiologically active form of the prohormone, vitamin D₃ (cholecalciferol), is 1,25-dihydroxyvitamin D₃ (1,25D₃). 1,25D₃ plays a key role in the regulation of calcium homeostasis and bone metabolism through effects on tissues such as bone, gut and kidney (1, 2). Non-classical roles for 1,25D₃ including the regulation of proliferation, differentiation and immune function have now been identified in a variety of cell types (3). The serum level of 1,25D₃ is highly regulated through synthesis facilitated by 1-alpha-hydroxylase (CYP27B1), and through inactivation by 24-hydroxylase (CYP24A1) (1, 2).

CYP24A1 is transcriptionally regulated by the interaction between the vitamin D receptor (VDR)-retinoid-X-receptor (RXR) heterodimer and vitamin D response elements (VDREs) on CYP24A1 gene (4-6). In the absence of 1,25D₃, VDR/RXR hetero-dimers bind to these VDREs and repress transcription through interactions with a co-repressor complex that has histone de-acetylase activity (7). In the presence of 1,25D₃, the co-repressor complex is released, permitting the recruitment of a co-activator complex that leads to the activation of the gene (8, 9). 1,25D₃ also stimulates rapid non-genomic effects in some cell-types via the ERK1/ERK2/ERK5, PKC, or JNK MAP kinase modules through a cell-membrane-associated VDR (3).

High CYP24A1 expression level is a common feature of several solid tumors (3, 10-15) and is associated with poorer prognosis (10, 14, 16). The increased intra-tumoral levels of CYP24A1 would lead to rapid degradation of 1,25D₃, thus, limiting the amount of 1,25D₃ locally in the tumor cells and abrogating the anti-proliferative, or pro-differentiation
effects of 1,25D$_3$ (10, 16, 17). Inhibition of CYP24A1 is expected to slow the catabolism of 1,25D$_3$, thereby enhancing the anti-proliferative effect of 1,25D$_3$ (18-21). Administration of 1,25D$_3$ in combination with a CYP24A1 inhibitor enhances the anti-tumor activity of 1,25D$_3$ (19, 22). However, most of the current CYP24A1 inhibitors, such as ketoconazole, are relatively non-specific, and strikingly increase the CYP24A1 expression level compared to cells treated with 1,25D$_3$ alone (19).

In the present study, we screened a small molecule library to identify novel CYP24A1 inhibitors using a CYP24A1 promoter-driving luciferase reporter assay. Furthermore, we expected that the new CYP24A1 inhibitor would enhance 1,25D$_3$-mediated function by inhibiting CYP24A1 expression.
CK2 inhibitor enhances vitamin D mediated anti-tumor effects

Materials and methods

Materials

1,25D₃ was purchased from Tetrionics (Madison, WI). 25D₃, LOPAC¹²⁸₀ and 4,5,6,7-tetrabromobenzimidazole (TBBz) were obtained from Sigma-Aldrich (St. Louis, MO). The dual-luciferase assay kit was supplied by Promega (Madison, WI). Mouse anti-CK2α (H-286, sc-9030) antibody and anti-actin antibody were from Santa Cruz biotechnology (Santa Cruz, CA). Anti-cleaved Caspase-3 (Asp175, #9661) antibody was purchased from Cell Signaling Technology (Danvers, MA). Anti-Ki-67 antibody was purchased from Leica Microsystems (NCL-Ki67p; Buffalo Grove, IL). TaqMan® Gene Expression Assay for CYP24A1 (Hs00167999_m1), CSNK2A1 (Hs00751002_s1), CDKN1A (Hs00355782_m1), Growth arrest and DNA-damage-inducible protein 45α (GADD45A, Hs00169255_m1) and the transient receptor potential vanilloid type 6 gene (TRPV6, Hs00367960_m1) were purchased from Applied Biosystems (Foster City, CA). ON-TARGET plus SMARTpool siRNA specific for human CSNK2A1 (CK2α1, L-003475), ON-TARGET plus Non-targeting Pool (D-001810), and DharmaFECT 2 transfection reagents were purchased from Dharmacon (Thermo Fisher Scientific Dharmacon, Lafayette, CO). Human RNA from 30 paired human prostate normal and primary tumor lesions were obtained from Department of Pathology, Roswell Park Cancer Institute and approved by Institutional review board.

Cell lines
CK2 inhibitor enhances vitamin D mediated anti-tumor effects

The prostate cancer cell lines DU145 and PC3 were purchased from American Type Culture Collection (ATCC) and used within 6 months after resuscitation. Cell lines were authenticated by ATCC with short tandem repeat (STR) DNA profiling and cytogenetic analysis. Cells were maintained in culture according to providers' protocols for a maximum of 10 passages (one month).

**Generation of stable reporter cell line**

pGL4.21 vector expressing the firefly luciferase gene under the control of *CYP24A1* promoter was constructed by the insertion of *CYP24A1* promoter using NheI and XhoI restriction enzyme sites (23). A stable human prostate cancer PC3 cell line expressing *CYP24A1* promoter-driving luciferase reporter (PC3/*CYP24A1*) was generated by transfection using lipofectamine 2000 followed by puromycin selection.

**Chemical library and high throughput screening**

Screening was performed by Small Molecule Screening Core Facility (SMSC) at the Roswell Park Cancer Institute using LOPAC\textsuperscript{1280} library. PC3/*CYP24A1* cells were seeded to 96-well plate (10\textsuperscript{4}/well) overnight. 120 nL of each compound or DMSO was added to the plate for 20 minutes using a JANUS robotic liquid handler (PerkinElmer) equipped with 96-pinn tool (V&P Scientific), followed by the addition of 1,25D\textsubscript{3} to a final concentration of 100 nM. The final concentration of the library compounds in the media was 10 μM. After 24-h incubation, luciferase activity for each well was assayed using SteadyGlo kit (Promega) and luminescence measured using Envision multilabel plate.
CK2 inhibitor enhances vitamin D mediated anti-tumor effects

reader (PerkinElmer). Hits were defined as over 50% inhibition of 1,25D₃ mediated CYP24A1 promoter-driving luciferase reporter activity.

CK2 small interfering RNA (siRNA)

PC3 cells were plated in 6-well plates (10⁵/well) overnight. Cells were transfected with 50 nM siRNA-CK2 or Non-targeting siRNA for 72 h using Dharma-FECT 2 transfection reagent following the manufacturer's instruction. Following transfection, the cells were treated with vehicle EtOH or 1,25D₃ for 6 h or 48 h and harvested for experiments as indicated.

Quantitative reverse transcriptase PCR (qRT-PCR)

Expression of CK2, CYP24A1, TRPV6, p21Waf1 and GADD45A mRNA was assessed by qRT-PCR using TaqMan® Gene Expression Assay and normalized to the human GAPDH and samples were analyzed in triplicate.

Immunoblotting analysis

Whole cell lysates were prepared and Western blot analysis performed as described previously (24).

Trypan blue exclusion assay

PC3 cells or PC3 cells transfected with siRNA-CK2 were plated in 6-well plates (3×10⁴/well) for 24 h and treated with 5 μM of TBBz or/and 100 nM of 1,25D₃ or 1000
CK2 inhibitor enhances vitamin D mediated anti-tumor effects

nM of 25D$_3$. Cells were trypsinized and viable cell count measured using ViCell XR (Beckman Coulter) on day 3, 6 and 9.

**Tumor growth assay**

PC3 cells (2×10$^6$) were inoculated subcutaneously into the right flank of male SCID mice (6-8 weeks old). At day 8–9 post implantation, when the tumors were palpable (6.5 × 5 mm), animals were treated with 1,25D$_3$ (15.5 µg/kg/d × 3, i.p. weekly), TBBz three times weekly (15 mg/kg/d, i.p., every 2 days), or the combination for 2 weeks. Body weight was monitored twice a week. Tumor growth was assessed and calculated as described previously (22, 25). The mice protocols used in tumor growth assay were approved by the Institutional Animal Care and Use Committee at Roswell Park Cancer Institute.

**Immunohistochemistry**

Tissue staining with anti-Ki-67 and anti-cleaved Caspase-3 was conducted as described previously (22).

**TUNEL assay**

Nuclear DNA fragmentation in situ was detected using TACS-XL In Situ Apoptosis Detection Kit according to the manufacture’s instruction (R&D system, Minneapolis, MN).

**Statistics**
CK2 inhibitor enhances vitamin D mediated anti-tumor effects

Statistical significance of data was determined by two-tailed Student’s t test. Wilcoxon Signed-Rank test was performed to compare the expression levels of CK2 in paired normal and tumor samples. 2×2 contingency table was performed to analyze the correlation between increased CYP24A1 expression and CK2 expression in paired normal and tumor human prostate samples.
Results

Screening of small molecules from LOPAC\textsuperscript{1280} Library by CYP24A1 promoter driving reporter assay

A stable human prostate cancer PC3 cell line expressing CYP24A1 promoter-driving luciferase reporter was generated by transfection using lipofectamine 2000 followed by puromycin selection. Screening of the LOPAC\textsuperscript{1280} library in this system resulted in the identification of 70 hits each of which had over 50% inhibition of 1,25D\textsubscript{3}-induced CYP24A1 promoter activity. (Fig. 1A) Excluding the hits with high toxicity, known from Small Molecule Screening Core (SMSC) database, twenty-one selected molecules were subjected to secondary dose-response experiments to confirm initial observations. Seventeen hits reduced 1,25D\textsubscript{3}-mediated CYP24A1 promoter activation (Fig. 1B). Among them, 4,5,6,7-tetabromobenzimidazole (TBBz) displayed the strongest inhibitory effect and was chosen for further investigation (Fig. 1A and 1B).

Repression of CYP24A1 transcriptional activity by TBBz

To confirm the results from the screening, we examined the effect of various concentration of TBBz on CYP24A1 promoter activity in PC3/CYP24A1 cells. Results showed that TBBz inhibited CYP24A1 promoter activity in a dose dependent manner (Fig. 1C). We also tested the effect of TBBz on endogenous and 1,25D\textsubscript{3}-regulated CYP24A1 expression. PC3 cells were treated with 1 or 5 μM of TBBz alone or followed by 10 nM, 30 nM and 100 nM of 1,25D\textsubscript{3}. qRT-PCR results showed that PC3 cells displayed low endogenous CYP24A1 mRNA level and dose-dependent induction of CYP24A1 mRNA expression by 1,25D\textsubscript{3} (Fig. 1D and Supplementary Fig. 1A). TBBz significantly ($P < 0.01$) reduced 1,25D\textsubscript{3}-induced CYP24A1 mRNA expression in a dose-
CK2 inhibitor enhances vitamin D mediated anti-tumor effects

dependent manner (Fig. 1D). Less induction of CYP24A1 expression by lower dose of 1,25D₃ was relatively less influenced by TBBz (Supplementary Fig. 1A). These results indicate that TBBz inhibits endogenous and 1,25D₃-induced CYP24A1 expression at the transcriptional level. Furthermore, we observed that 25D₃, the precursor to 1,25D₃ also induced CYP24A1 mRNA expression in PC3 cells and TBBz inhibits 25D₃-induced CYP24A1 expression at the transcriptional level in PC3 cells (Supplementary Fig. 2A).

Reduction of CYP24A1 expression by siRNA-CK2

TBBz is a selective protein kinase CK2 inhibitor (26). To investigate whether CK2 plays a role in the regulation of CYP24A1 expression, siRNA-CK2 was transfected in prostate cancer PC3 or DU145 cells for 72 hours followed by the addition of 1,25D₃. CYP24A1 mRNA and CYP24A1 protein were measured by qRT-PCR and Western blot, respectively. Results showed that PC3 and DU145 cells express CK2 and CK2 was effectively knocked down by siRNA-CK2 in PC3 and DU145 cells compared to control siRNA (Fig. 2A and 2B). 1,25D₃ significantly (P < 0.01) increased CYP24A1 expression in PC3 cells, which express a low level of endogenous CYP24A1 (Fig. 2A and 2C, respectively), and in DU145 cells, which display a high level of endogenous CYP24A1 (Fig. 2B and 2D, respectively). Transfection with siRNA-CK2 significantly reduced 1,25D₃-induced CYP24A1 expression at both mRNA and protein level in PC3 (Fig. 2A and 2C) and DU145 cells (Fig. 2B and 2D) as compared with the mock-transfected or siRNA control transfected samples. These results indicate that CK2 plays a role in regulation of 1,25D₃-induced CYP24A1 expression.
Differential effects of siRNA-CK2 on 1,25D$_3$-induced $TYPV6$, $p21^{Waf1}$ and $GADD45A$ mRNA expression

To investigate whether silencing of CK2 affects the expression of other vitamin D target genes, $TRPV6$, $p21^{Waf1}$ and $GADD45A$ mRNA expression was measured by qRT-PCR in CK2 knockdown PC3 cells. 1,25D$_3$ induced $TRPV6$, $p21^{Waf1}$ and $GADD45A$ mRNA expression. siRNA-CK2 significantly ($P < 0.01$) reduced 1,25D$_3$-induced $TRPV6$ mRNA expression as compared to the mock-transfected or siRNA control transfected cells (Fig. 3A). In contrast, knockdown of CK2 markedly increased $p21^{Waf1}$ and slightly increased $GADD45A$ mRNA expression (Fig. 3B and 3C). These results indicate that silencing of CK2 differentially affects the expression of vitamin D target genes.

Correlation of increased CYP24A1 expression with increased CK2 expression in human prostate tumors

We analyzed mRNA expression of CYP24A1 and CK2 in 30 matched pair of human normal and tumor prostate samples by qRT-PCR. CK2 expression was significantly increased in prostate tumor lesions compared to normal lesions ($P = 0.0224$) (Fig. 4). There was no correlation of the level of CYP24A1 expression and CK2 expression with Gleason Score. To determine whether tumor samples with increased CYP24A1 expression correlated with increased CK2 expression compared to normal samples, we built a 2×2 contingency table by dividing the 30 samples based on the CYP24A1 expression change ($\geq 1.5$ fold up vs. other) and CK2 expression change ($\geq 1.5$ fold up vs. other). Seven samples display increased CYP24A1 expression in a total of 30 prostate tumors compared to matched normal prostate samples. Four of the 7 samples with
increased $CYP24A1$ expression have increased CK2 expression. However, among the remaining 23 samples with low $CYP24A1$ expression, only 3 samples have high CK2 expression (Table 1). Fisher’s exact test shows that increased $CYP24A1$ expression is significantly associated with increased CK2 expression in tumor ($P=0.0331$). These data indicate that CK2 may be involved in regulation of increased $CYP24A1$ expression in prostate cancer.

Enhancement of 1,25D$_3$ anti-proliferative activity by TBBz or siRNA-CK2

To ascertain the potential therapeutic role of CK2 inhibitors in 1,25D$_3$ anti-tumor action, cell viability and cell proliferation was examined using the trypan blue exclusion assay after treatment with 1,25D$_3$, TBBz, or the combination of 1,25D$_3$ and TBBz for 9 days. Combination treatment of 1,25D$_3$ and TBBz resulted in a significant ($P < 0.05$) enhancement of 1,25D$_3$ anti-proliferative effect in PC3 cells (Fig. 5A). We also measured $CYP24A1$ mRNA expression on day 1 and day 9. We observed that $CYP24A1$ mRNA expression kept lower in PC3 cells treated with the combination of 1,25D$_3$ and TBBz which showed the most antiproliferative activity compared to cells treated with 1,25D$_3$ alone (Supplementary Fig. 1B). Instead of 1,25D$_3$, 25D$_3$ in combination of TBBz also caused a greater inhibition of proliferation in PC3 cells than when treated with either agent alone (Supplementary Fig. 2B).

To more specifically investigate the importance of CK2 in 1,25D$_3$ anti-proliferative effect, siRNA-CK2 was employed. siRNA-CK2 significantly ($P < 0.05$) enhanced 1,25D$_3$
CK2 inhibitor enhances vitamin D mediated anti-tumor effects

anti-proliferative effect in PC3 cells (Fig. 5B). This indicates that CK2 inhibition is anti-
 proliferative and enhances 1,25D3 anti-proliferative effect.

**Enhancement of 1,25D3 anti-tumor activity by TBBz in vivo**

Having demonstrated the efficacy of the combination treatment of 1,25D3 and TBBz *in vitro*, we next assessed both toxicity and efficacy of the combination treatment in a PC3 prostate tumor xenograft mouse model. We observed a marked inhibition of tumor
growth by the combination of 1,25D3 and TBBz, compared to 1,25D3 or TBBz alone (Fig. 6A). Mice grew normally without suffering from weight loss at a dose sufficient to
induce anti-tumor effect (Fig. 6B). These results indicate that CK2 inhibitor TBBz
enhances 1,25D3 anti-tumor activity *in vivo*.

**Effect of the combination of 1,25D3 and TBBz on tumor cell CYP24A1 expression,**

**proliferation and apoptosis in *in vivo***

To investigate the effect of TBBz on *CYP24A1* expression *in vivo*, tumor tissues were
harvested at the end of the treatment described in Fig. 5A, and *CYP24A1* mRNA
expression was measured by qRT-PCR. 1,25D3 increased *CYP24A1* expression and TBBz
reduced *CYP24A1* expression in tumors as compared to saline group (Fig. 6C). 
Furthermore, TBBz significantly (*P* < 0.05) reduced 1,25D3-induced *CYP24A1*
expression (Fig. 6C). These observations were consistent with the results obtained in the
*in vitro* study.
CK2 inhibitor enhances vitamin D mediated anti-tumor effects

To further elucidate the molecular mechanisms for the anti-tumor activity of 1,25D₃ and TBBz \textit{in vivo}, we examined the proliferation marker Ki-67 and apoptosis marker cleaved caspase-3 as well as in situ DNA fragmentation (TUNEL) in tumor tissues (Fig. 6D). The results showed that saline-treated tumor tissue had strong Ki-67 staining, 1,25D₃ or TBBz reduced Ki-67 staining (Fig. 6D). The combination of 1,25D₃ and TBBz further reduced Ki-67 staining (Fig. 6D). We also observed that saline group did not have positive cleaved caspase-3 staining, whereas 1,25D₃ or TBBz treatment alone induced caspase-3 cleavage in the tumor tissue (Fig. 6D). The combination of 1,25D₃ and TBBz further enhanced caspase-3 cleavage (Fig. 6D). The effect of 1,25D₃ and TBBz on apoptosis was further confirmed by TUNEL assay (Fig. 6D). These results clearly indicate the potential usefulness of the combination of 1,25D₃ and CK2 inhibitors in prostate cancer therapy.
Discussion

The majority of $\text{CYP24A1}$ inhibitors developed so far target the enzyme activity. However, decreased enzyme activity with current $\text{CYP24A1}$ inhibitors is often associated with increased enzyme expression which negatively impacts on the vitamin D-mediated anti-tumor activity (19, 21, 27). In this study, the strategy we utilized to identify new $\text{CYP24A1}$ inhibitors differs from previously described (28). We established a stable PC3 cell line, which express luciferase driven by $\text{CYP24A1}$ promoter, to screen a small molecular library containing 1280 compounds. We identified 17 new $\text{CYP24A1}$ inhibitors, TBBz being the strongest was selected for further characterization, which revealed a new $\text{CYP24A1}$ expression regulating molecule, protein kinase CK2. Analysis of 30 paired normal and tumor human prostate samples showed that increased $\text{CYP24A1}$ expression is related to increased CK2 expression in tumor. Moreover, we observed a significant enhancement of 1,25D$_3$ anti-tumor activity by inhibiting CK2 \textit{in vitro} or \textit{in vivo}. The effects were associated with the reduction of $\text{CYP24A1}$ expression, inhibition of proliferation and the induction of apoptosis in tumors.

Protein kinase CK2 is an evolutionarily conserved serine/threonine kinase which is ubiquitously expressed in human tissues. CK2 is located both in cytosol and nucleus (29, 30). Overexpression of CK2 has been noted in a variety of human cancers including prostate cancer and correlates with a poor clinical outcome (31-34). Inhibition of CK2 activity reduced cell proliferation in prostate cancer cells (35, 36). The role for CK2 in the regulation of $\text{CYP24A1}$ gene expression in tumor has not been described before. Our study shows that CK2 positively regulates $\text{CYP24A1}$ expression. We further show that
CK2 inhibitor enhances vitamin D mediated anti-tumor effects

CK2 expression was higher in tumor lesions compared to normal lesions ($P = 0.0224$) (Fig. 4). Increase of CK2 expression was significantly ($P=0.0331$) associated with increased CYP24A1 expression in these prostate tumor samples. These observations suggest that CK2 may serve as a mechanism for controlling \textit{CYP24A1} expression in human cancers, and therefore supporting the use of CK2 inhibitors for cancer treatment in combination with 1,25D$_3$.

\textit{CYP24A1} expression is heterogeneous in prostate cancer (23). It is noteworthy that three human prostate tumor samples with high \textit{CK2} expression did not express high level of \textit{CYP24A1} and three prostate tumor samples with high \textit{CYP24A1} expression did not express high level of \textit{CK2} compared to normal lesions (table 1). These data suggest that the level of \textit{CK2} expression does not entirely account for the level of \textit{CYP24A1} expression in human prostate tumor. Previous studies indicated multiple events are associated with \textit{CYP24A1} expression in cancer, such as methylation and histone modification associated with the \textit{CYP24A1} promoter (3, 23, 37), amplification at the \textit{CYP24A1} locus (13) and miRNA regulation (38).

We also observed that the silencing of CK2 differentially affects vitamin D target genes. We observed the significant reduction of 1,25D$_3$-induced \textit{TRPV6} in siRNA-CK2 transfected PC3 cells. Up-regulation of \textit{TRPV6} by 1,25D$_3$ in prostate cancer cells is considered to be pro-proliferative by increasing Ca$^{2+}$-uptake (39, 40). On the other hand, siRNA-CK2 enhanced 1,25D$_3$-mediated induction of \textit{p21$^{Waf1}$} and \textit{GADD45A}. \textit{p21$^{Waf1}$} is accounted in part for the anti-proliferative effects of VDR ligands on some cell types,
CK2 inhibitor enhances vitamin D mediated anti-tumor effects

such as prostate cancer (19, 41-43). \textit{GADD45A} is identified as a primary target gene for 1,25D₃ in ovarian, testicular and prostate cancer cells (19, 44, 45). The increase in \textit{GADD45A} expression leads to a decrease of cyclin B and induces G2/M cell cycle arrest (45, 46). In the present study, the reduction of \textit{CYP24A1} and \textit{TRPV6} expression and the increase in the \textit{p21^{Waf1}} and \textit{GADD45A} expression by the combination of 1,25D₃ and siRNA-CK2 may be reflective of the co-operative growth inhibition observed from the cell-proliferation assay.

However, the exact mechanisms underlying the effect of CK2 on 1,25D₃-mediated \textit{CYP24A1} induction remain unclear despite reports of CK2-mediated phosphorylation of purified VDR at serine^{208} and VDRE construct transactivation in COS-7 kidney cells co-transfected with VDR and CK2 (47-49). Studies have shown that phosphorylation of hVDR at serine^{208} does not affect the ability of VDR to bind to DNA and is not obligatory for 1,25D₃ action, but may contribute to the modulation of the affinity of VDR for the vitamin D interacting protein (DRIP) complex, therefore increasing its ability to transactivate target promoters (50). At present, we cannot rule out additional mechanisms in the interaction between CK2 and vitamin D target genes as differential effect was observed on \textit{TRPV6}, \textit{p21^{Waf1}}, and \textit{GADD45A}.

In summary, we developed a new strategy to identify novel \textit{CYP24A1} inhibitors. Furthermore, we found that protein kinase CK2 is involved in the regulation of \textit{CYP24A1} and other vitamin D target genes. CK2 inhibitor TBBz significantly enhances 1,25D₃
CK2 inhibitor enhances vitamin D mediated anti-tumor effects

anti-tumor activity *in vitro* and *in vivo*. These findings provide support for the combination treatment of CK2 inhibitor and vitamin D in prostate cancer therapy.
CK2 inhibitor enhances vitamin D mediated anti-tumor effects

Acknowledgments

We thank Dr. Adam Karpf and Dr. Elizabeth A Griffiths for helpful discussions, Yan Li for statistical assistance, Mrs. Rui-Xian Kong for her excellent technical assistance, and Ms. Ellen Karasik for her excellent technical assistance in immunohistochemistry study.
CK2 inhibitor enhances vitamin D mediated anti-tumor effects

References

CK2 inhibitor enhances vitamin D mediated anti-tumor effects


CK2 inhibitor enhances vitamin D mediated anti-tumor effects

CK2 inhibitor enhances vitamin D mediated anti-tumor effects


Figure Legends

**Figure 1. Identification of CYP24A1 small molecular inhibitors by screening**

**LOPAC compounds.** (A) PC3/CYP24A1 cells containing CYP24A1 promoter-driving luciferase were seeded into 96-well plates overnight. The LOPAC\textsuperscript{1280} library of pharmacologically active compounds was dispensed at a final concentration of 10 μM per compound followed by the addition of 100 nM 1,25D\textsubscript{3} for 24 hours. Luciferase activity for each well was assayed and luminescence measured. Each dot represents the value of luminescence. (B) Excluding the hits with high toxicity, known from SMSC database, 21 selected compounds were subjected to secondary dose-response experiments to confirm initial observations. ) PC3/CYP24A1 cells were treated with compounds at indicated concentration followed by 1,25D\textsubscript{3}. CYP24A1 promoter luciferase activity was measured and fold change of luciferase value was calculated for the ratio of (1,25D\textsubscript{3}-induced luciferase activity in the presence of the compound) to (1,25D\textsubscript{3}-induced luciferase activity in the absence of the compound). (C) PC3 cells were transfected with the CYP24A1 promoter constructs along with Renilla luciferase control construct. Twenty-four hours post transfection, cells were treated with TBBz as indicated and 1,25D\textsubscript{3} (100 nM) for additional 24 hours and harvested, and luciferase activities were measured using the Dual-Luciferase Reporter Assay System. The experiment was repeated twice to confirm the reproducibility of results. (*, \(P < 0.05\)). (D) PC3 cells were treated with TBBz as indicated followed by 1,25D\textsubscript{3} (100 nM). Expression of CYP24A1 mRNA was assessed by qRT-PCR and normalized to human GAPDH and all samples were analyzed in triplicate.
CK2 inhibitor enhances vitamin D mediated anti-tumor effects

**Figure 2.** siRNA-mediated silencing of CK2 reduces 1,25D₃-induced CYP24A1 expression. PC3 (A, C) or DU145 (B, D) cells were transfected with ON-TARGET plus SMARTpool siRNA-CK2 or siRNA control (siRNA-CTR) for 72 h. Cells were then treated with either vehicle EtOH or 1,25D₃ (100 nM) for 24 h or 48 h and harvested for qRT-PCR (C, D) and immunoblotting analysis (A, B).

**Figure 3.** Effect of siRNA-CK2 on TYPV6, p21Waf1 and GADD45A mRNA expression. PC3 cells were transfected with siRNA-CK2 or siRNA-control for 72 h. Cells were then treated with either EtOH or 1,25D₃ (100 nM) for 6 hours. TYPV6 (A), p21Waf1 (B) and GADD45A (C) mRNA expression were measured and normalized to human GAPDH and all samples were analyzed in triplicate.

**Figure 4.** CK2 expression in normal and tumor human prostate tissues. CK2 mRNA expression in human matched prostate tumor and normal lesions was measured and normalized to human GAPDH by qRT-PCR. The difference of CK2 mRNA expression between matched tumor and normal lesions was represented as the ratio of CK2 expression of tumor to normal lesions. Each dot represents the ratio of CK2 expression in tumor to normal lesion.

**Figure 5.** Enhancement of inhibitory effect of 1,25D₃ in prostate cancer cells by TBBz or siRNA-CK2. (A) PC3 cells were treated with TBBz (5 μM), 1,25D₃ (100 nM) or the combination of TBBz and 1,25D₃. Viable cells were determined using trypan blue exclusion assay on day 3, 6 and 9. (B) PC3 cells were transfected with siRNA-CK2 or
CK2 inhibitor enhances vitamin D mediated anti-tumor effects

siRNA control for 72 h. Following transfection, cells were treated with EtOH or 1,25D$_3$ (100 nM). Viable cells were determined on day 3, 6 and 9. (*, $P < 0.01$)

**Figure 6. TBBz enhances 1,25D$_3$ anti-tumor effect in PC3 xenograft mouse model.**

PC3 prostate cancer cells were inoculated subcutaneously into the right flank of male SCID mice. When the tumors were palpable, animals were treated intraperitoneally with saline, 1,25D$_3$, TBBz or the combinations of 1,25D$_3$ and TBBz as described in Material and Methods. (A) Tumor growth was monitored by measuring tumor size three times per week. Tumor volumes were calculated by $(\text{length} \times \text{width}^2)/2$. (*, $P < 0.01$). (B) Mouse weight was measured three times per week. (C) PC3 tumors were harvested after the treatment, and *CYP24A1* mRNA expression in tumor tissues was determined by qRT-PCR. (D) PC3 tumors were harvested after the treatment, and immunohistochemical staining of Ki-67 and cleaved Caspase-3 in tissues was performed. Nuclear DNA fragmentation in situ was detected using TACS-XL In Situ Apoptosis Detection Kit in tumor tissues ($\times$ 200).
Table 1. mRNA expression of CYP24A1 and CK2 in 30 human prostate tumors compared to normal lesion

<table>
<thead>
<tr>
<th>Fold change</th>
<th>CK2</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 1.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
</tr>
<tr>
<td>&lt; 1.5</td>
<td>3</td>
</tr>
</tbody>
</table>
Figure 2

A

<table>
<thead>
<tr>
<th></th>
<th>EtOH</th>
<th>1,25D3</th>
</tr>
</thead>
<tbody>
<tr>
<td>CK2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP24A1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th></th>
<th>EtOH</th>
<th>1,25D3</th>
</tr>
</thead>
<tbody>
<tr>
<td>CK2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP24A1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

\[ P < 0.01 \]

D

\[ P < 0.01 \]
Figure 4

Ratio (Tumor/normal)

CK2 mRNA expression
Inhibition of protein kinase CK2 reduces CYP24A1 expression and enhances 1,25-dihydroxyvitamin D3 anti-tumor activity in human prostate cancer cells

Wei Luo, Wei-Dong Yu, Yingyu Ma, et al.

Cancer Res Published OnlineFirst January 28, 2013.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-12-4119

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2013/01/28/0008-5472.CAN-12-4119.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.